Sugi Predict

Sugi Predict / Targets / F13A1

F13A1

Coagulation factor XIII A chain · P00488 · F13A1 on Sugi Atlas →

31,041 patent compounds predicted against F13A1, 17,654 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL477386 SCHEMBL477386 0.61 12/20
SCHEMBL711933 SCHEMBL711933 0.58 9/20
SCHEMBL309691 SCHEMBL309691 0.49 9/20
SCHEMBL392870 SCHEMBL392870 0.55 8/20
SCHEMBL308426 SCHEMBL308426 0.53 8/20
SCHEMBL566974 SCHEMBL566974 0.50 8/20
SCHEMBL710366 SCHEMBL710366 0.64 7/20
SCHEMBL309243 SCHEMBL309243 0.64 7/20
SCHEMBL567503 SCHEMBL567503 0.53 7/20
SCHEMBL567385 SCHEMBL567385 0.49 7/20
SCHEMBL568155 SCHEMBL568155 0.49 7/20
SCHEMBL477365 SCHEMBL477365 0.49 7/20
SCHEMBL435164 SCHEMBL435164 0.49 7/20
SCHEMBL16899 SCHEMBL16899 0.47 7/20
SCHEMBL458895 SCHEMBL458895 0.52 6/20
SCHEMBL56379 SCHEMBL56379 0.47 6/20
SCHEMBL168530 SCHEMBL168530 0.60 5/20
SCHEMBL265005 SCHEMBL265005 0.52 5/20
Cerulenin Cerulenin (SCHEMBL41207) 1.00 4/20
SCHEMBL439369 SCHEMBL439369 0.79 4/20

Clinical trials — most relevant to F13A1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Enhancement of the Haemostatic Effect of Platelets in the Presence of High Normal Concentrations of Von Willebrand Factor PHASE4RECRUITING
Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study) PHASE4RECRUITING
Levonorgestrel-releasing Intrauterine System in Patients With Endometriosis PHASE4COMPLETED
PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A） PHASE4RECRUITING
An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A. PHASE3COMPLETED
Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A PHASE3COMPLETED
Effect of Hyperglycemia in PAI-1 Activity and the Relationship With Outcome in Severe Sepsis and Septic Shock PHASE2/PHASE3COMPLETED
Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725 PHASE3COMPLETED
Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B PHASE3WITHDRAWN
Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer PHASE3COMPLETED
Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome PHASE1COMPLETED
Safety and Dosing Evaluation of REG1 Anticoagulation System PHASE1COMPLETED
Hypolipemic Treatment in Acute Coronary Syndrome (ACS): Antithrombotic Effects nanUNKNOWN
Correlation Between PT and INR to Factor 7 nanUNKNOWN
Risk Markers in the Acute Coronary Syndromes nanCOMPLETED
Estimation of Coagulation Factor XIII Activity Based on the Initial Plasma Fibrinogen Level in Trauma nanCOMPLETED
Heparin Management During Cardiopulmonary Bypass in Children nanCOMPLETED
Risk Factors of Neonatal Thrombosis nanCOMPLETED
Cross-sectional Study on Prevalence of Coagulation Factors Deficiency in Assiut University Children Hospital nanUNKNOWN
A Study That Collects Participant Data and Biospecimens to Analyze Pathogenic Exosomes That Mediate Increased Vascular Dementia Risk in Individuals With Herpes Zoster. nanRECRUITING
Hemostasis in Sickle Cell Disease--Infancy to Adulthood nanCOMPLETED
The Role of Platelet Surface α2β1 Integrin Expression as a Risk Factor in Thrombotic and/or Bleeding Complications nanCOMPLETED
Rare Bleeding Disorders in the Netherlands nanUNKNOWN
Influence of Cardiac Implantable Electronic Devices on the Hemostatic System nanCOMPLETED
Hormone Replacement Therapy and Prothrombotic Variants nanCOMPLETED
Thrombophilic Risk Factors in Preterm and Infants Treated at Ha'Emek Medical Center Between the Years 1990 to 2010 nanUNKNOWN
Mechanism and Repository Study for the Red Cell Storage Duration Study nanCOMPLETED
The Malmö International Brother Study (MIBS) nanCOMPLETED
Factor XIII and Other Biomarkers in ST Segment Elevation Myocardial Infarction nanCOMPLETED
The Contact Activation System and Ulcerative Colitis nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a F13A1 binder may also engage these)

ProteinNameSimilarity
O08619 — 1.000 O08619 →
Q8BH61 — 1.000 Q8BH61 →
Q05187 — 0.997 Q05187 →
Q8BZH1 — 0.995 Q8BZH1 →
P52181 — 0.995 P52181 →
Q9WVJ6 — 0.995 Q9WVJ6 →
Q08189 — 0.995 Q08189 →
A6QP57 — 0.995 A6QP57 →
TGM1 Protein-glutamine gamma-glutamyltransferase K 0.995 landscape →
P23606 — 0.994 P23606 →
P21981 — 0.994 P21981 →
P08587 — 0.993 P08587 →
D4A5U3 — 0.993 D4A5U3 →
P51176 — 0.992 P51176 →
P22758 — 0.992 P22758 →
P52183 — 0.992 P52183 →
Q9JLF6 — 0.992 Q9JLF6 →
P49221 — 0.992 P49221 →
Q9GLK0 — 0.991 Q9GLK0 →
Q99041 — 0.990 Q99041 →
TGM3 Protein-glutamine gamma-glutamyltransferase E 0.989 landscape →
TGM2 Protein-glutamine gamma-glutamyltransferase 0.989 landscape →
Q01841 — 0.988 Q01841 →
B4NBB0 — 0.986 B4NBB0 →
B4LX81 — 0.984 B4LX81 →
P34647 — 0.984 P34647 →
P97311 — 0.984 P97311 →
O35646 — 0.984 O35646 →
B3M383 — 0.984 B3M383 →
Q9Y6Q1 — 0.984 Q9Y6Q1 →